| (Values in U.S. Thousands) | Dec, 2025 | Sep, 2025 | Jun, 2025 | Mar, 2025 | Dec, 2024 |
| Sales | 7,300 | 6,830 | 8,510 | 10,390 | 8,690 |
| Sales Growth | +6.88% | -19.74% | -18.09% | +19.56% | +6.50% |
| Net Income | -9,600 | -12,420 | -12,360 | -10,260 | -10,600 |
| Net Income Growth | +22.71% | -0.49% | -20.47% | +3.21% | +8.30% |
Maxcyte Inc (MXCT)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] by (Cboe BZX)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] [[ item.lastPriceExt ]] [[ item.priceChangeExt ]] ([[ item.percentChangeExt ]]) [[ item.tradeTimeExt ]]
for [[ item.sessionDateDisplayLong ]]
MaxCyte Inc. is a provider of cell-engineering enabling technology and is responsible cell-based therapies. MaxCyte Inc. is headquartered in Gaithersburg, Maryland.
Fiscal Year End Date: 12/31